
BioEclipse Therapeutics: A clinical-stage company innovating immuno-oncology therapeutics.
BioEclipse Therapeutics, founded with a mission to revolutionize cancer treatment, is a clinical-stage company specializing in immuno-oncology therapeutics. Utilizing its proprietary platform technology, BioEclipse aims to destroy cancer cells while empowering the patient's immune system to recognize, attack, and clear cancer. The company's flagship product, CRX100, represents the next generation of immunotherapy, targeting solid tumors that have been resistant to conventional treatments.
Notable figures associated with BioEclipse Therapeutics include experienced leaders in oncology and biotechnology. The company has attracted significant attention from investors focused on innovative cancer treatments. Key achievements include advancing CRX100 into clinical trials, demonstrating promising preclinical results, and securing strategic partnerships. BioEclipse's impact lies in its potential to offer groundbreaking solutions for patients with challenging cancer types, contributing to the broader field of oncology therapeutics.

Checkpoint Therapeutics
checkpointtx.com

Immune-Onc Therapeutics
immuneonc.com

OnCusp Therapeutics
oncusptx.com

Xios Therapeutics

NextCure
nextcure.com

OmniCyte
omnicyte.com

Asher Bio
asherbio.com

INmune Bio
inmunebio.com

Metaclipse Therapeutics

Eikon Therapeutics
eikontx.com

Avenge Bio
avengebio.com

Oncofactor
oncofactor.com

ImmunoMet Therapeutics
immunomet.com

EpicentRx

Eureka Therapeutics
eurekainc.com
Companies similar to BioEclipse Therapeutics include Checkpoint Therapeutics, Immune-Onc Therapeutics, OnCusp Therapeutics and Xios Therapeutics.
BioEclipse Therapeutics was founded in 2006.
BioEclipse Therapeutics' headquarters is located in San Francisco, CA, US.
BioEclipse Therapeutics' most recent funding round was for $8M (USD) in April 2022.
As of Apr 26, 2022, BioEclipse Therapeutics has raised a total of $15.7M (USD).
BioEclipse Therapeutics has 7 employees as of Feb 5, 2024.